These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 24415364)

  • 1. Denosumab in hypercalcemia of malignancy: a case series.
    Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
    J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma.
    Ashihara N; Nakajima K; Nakamura Y; Kobayashi M; Shirahata K; Maeda C; Uehara T; Gomi D; Ito N
    Intern Med; 2016; 55(23):3453-3457. PubMed ID: 27904108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab-Associated Severe Hypocalcemia in a Patient With Chronic Kidney Disease.
    Salim SA; Nair LR; Thomas L; Garla V; Palabindala V; Agarwal M; Fülöp T
    Am J Med Sci; 2018 May; 355(5):506-509. PubMed ID: 29753381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.
    Nasser SM; Sahal A; Hamad A; Elazzazy S
    J Oncol Pharm Pract; 2019 Dec; 25(8):1846-1852. PubMed ID: 31694497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab for treatment of hypercalcemia of malignancy.
    Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Denosumab normalized plasma calcium concentration in malignancy-associated hypercalcaemia].
    Størling L; Villadsen GE; Krogh K; Vestergaard P
    Ugeskr Laeger; 2014 Jul; 176(30):. PubMed ID: 25292242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
    Tai N; Inoue D
    Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab: a new agent in the management of hypercalcemia of malignancy.
    Thosani S; Hu MI
    Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of denosumab in parathyroid carcinoma with refractory hypercalcemia.
    Tong CV; Hussein Z; Noor NM; Mohamad M; Ng WF
    QJM; 2015 Jan; 108(1):49-50. PubMed ID: 25099611
    [No Abstract]   [Full Text] [Related]  

  • 10. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
    Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
    Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using denosumab to treat immobilization hypercalcemia in a post-acute care patient.
    Booth KA; Hays CI
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3531-5. PubMed ID: 25033064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
    McMahan J; Linneman T
    Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis.
    Yerram P; Kansagra S; Abdelghany O
    J Oncol Pharm Pract; 2017 Apr; 23(3):179-184. PubMed ID: 26830549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral Hypercalcemia in a Patient with Cholangiocellular Carcinoma - Effective Therapy with Denosumab.
    Harsch IA; Konturek PC
    Am J Case Rep; 2019 Sep; 20():1325-1330. PubMed ID: 31492829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
    Hu MI; Glezerman I; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Ying W; Jain RK
    J Natl Cancer Inst; 2013 Sep; 105(18):1417-20. PubMed ID: 23990665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of bisphosphonates for malignant hepatic tumor with hypercalcemia.
    Oida T; Mimatsu K; Kano H; Kawasaki A; Kuboi Y; Fukino N; Kida K; Amano S
    Hepatogastroenterology; 2012; 59(114):444-7. PubMed ID: 22353513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting.
    Huynh AL; Baker ST; Stewardson AJ; Johnson DF
    Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1274-1278. PubMed ID: 27255807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
    Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
    Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
    Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
    J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab for the treatment of bisphosphonate resistant hypercalcemia in a hemodialysis patient.
    Dahmani O; Sophoclis C; Kebir M; Bouguern D; Sakho A; Demarchi P
    Saudi J Kidney Dis Transpl; 2017; 28(1):154-157. PubMed ID: 28098117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.